ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Philadelphia, PA, USA:

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Philadelphia, Pennsylvania, United States and 9 other locations

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...

Active, not recruiting
Breast Cancer
Circulating Tumor DNA
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Philadelphia, Pennsylvania, United States and 8 other locations

the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Enzalutamide
Behavioral: assessment

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Allentown, Pennsylvania, United States and 11 other locations

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Philadelphia, Pennsylvania, United States and 11 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Philadelphia, Pennsylvania, United States and 166 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Placebo
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Philadelphia, Pennsylvania, United States and 199 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Philadelphia, Pennsylvania, United States and 516 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Philadelphia, Pennsylvania, United States and 505 other locations

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Active, not recruiting
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Philadelphia, Pennsylvania, United States and 17 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Newark, Delaware, United States and 192 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems